Swiss Re AG SREN.SW
Composite 56/100; the shares have moved about 19% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 32/100 — a moderate mark against it.
Income ranks 86/100 — a strong point in its favour. Valuation ranks 70/100 — a moderate point in its favour. Momentum ranks 65/100 — a moderate point in its favour.
Growth ranks 32/100 — a moderate mark against it.
What the company does Swiss Re AG is a global reinsurer offering property & casualty, life & health reinsurance, and corporate solutions to insurers, corporations, and public entities. Its Property & Casualty segment covers risks like property, engineering, marine, and cyber, while Life & Health focuses on mortality and longevity products. Corporate Solutions provides tailored risk-transfer programs.
Key financials Swiss Re reports ROE 19.5%, ROA 3.2%, and net margin 11.8%. Revenue declined -2.0% but EPS grew 18.6%. Debt/Equity is 0.31 with net debt/EBITDA at 0.64 and a current ratio of 2.79. Forward P/E is 8.79 (PEG 0.41), P/E 10.66, and P/B 1.92.
Stock health Momentum shows +5.91% over 3m and +17.75% over 6m, yet -2.31% over 12m and -8.23% below the 52-week high. RSI(14) is 59.60. Sideravia scores valuation at 85.5/100 (top decile) but quality at 47.2, income at 35.7, and strength at 46.3.
Price vs fair value The stock trades at a DISCOUNT of 75.00% versus our fair-value estimate and at a PREMIUM of 6.61% versus the 12-month analyst target. - Discount to fair value reflects low valuation multiples (P/E 10.66, fwd 8.79) and high valuation percentile (85.5/100) (Valuation percentile 85.5/100; Fwd P/E 8.79). - Premium to target may stem from modest growth (-2.0% revenue) despite strong EPS growth (18.6%) (Revenue growth -2.0%, EPS growth 18.6%). - Below-average quality (47.2) and income (0.0% yield) scores may cap upside (Quality 47.2, Income 35.7).
Looking forward Forward PEG of 0.41 suggests undemanding growth-adjusted valuation, but weak revenue momentum and low income yield temper appeal. Analyst dispersion (16.0) and valuation percentile indicate mixed expectations. Focus on execution in core reinsurance lines and capital management to validate the discount.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.